Articles

This real-world analysis investigates the relationship between ESR1-positivity rates and the length of exposure to endocrine therapy with or without cyclin-dependent kinase (CDK)4/6 inhibitors in hormone receptor (HR)-positive/HER2-negative breast cancer. Read More ›

This real-world study examines the role of ovarian function suppression as adjuvant therapy in hormone receptor (HR)-positive/HER2-positive premenopausal breast cancer patients who achieved pathologic complete response following neoadjuvant chemotherapy, analyzing its use within routine clinical practice. Read More ›

This study examines treatment duration and patterns of follow-up therapies after first-line cyclin-dependent kinase (CDK)4/6 inhibitor plus aromatase inhibitor use in hormone receptor (HR)-positive/HER2-negative metastatic breast cancer in US clinical practice. Read More ›

Updated results from the monarchE trial indicate positive primary overall survival outcomes of adjuvant abemaciclib combined with endocrine therapy in hormone receptor (HR)-positive/HER2-negative high-risk early breast cancer. Read More ›

A preliminary analysis of the SOLTI-RIBOLARIS trial shows reduced recurrence risk in high-risk estrogen receptor (ER)-positive/HER2-negative breast cancer patients treated with neoadjuvant ribociclib and endocrine therapy, highlighting recurrence dynamics and potential clinical benefits. Read More ›

The POSITIVE trial’s 5-year follow-up reports favorable pregnancy outcomes and does not appear to increase the risk of breast cancer recurrence at 5 years in women with endocrine-responsive breast cancer. Read More ›

The 5-year landmark analysis of the NATALEE trial highlights sustained improvements with adjuvant ribociclib combined with nonsteroidal aromatase inhibitors (NSAIs) for hormone receptor (HR)-positive/HER2-negative early breast cancer. Read More ›